|
Clinical parameter
|
MSD (n = 1891)
|
Haplo (n = 413)
|
p
|
|---|
|
Conditioning intensity
| | | |
|
Myeloablative conditioning, n (%)
|
1574 (83.2%)
|
281 (68%)
|
< 0.0001
|
|
Reduced intensity conditioning, n (%)
|
317 (16.8%)
|
132 (32%)
| |
|
TBI
| | | |
|
CT
|
663 (35.1%)
|
237 (57.4%)
|
< 0.0001
|
|
TBI
|
1228 (64.9%)
|
176 (42.6%)
| |
|
Graft source
| | | |
|
Bone marrow
|
351 (18.6%)
|
191 (46.2%)
|
< 0.0001
|
|
Peripheral blood
|
1540 (81.4%)
|
222 (53.8%)
| |
|
PTCy
| | | |
|
No PTCy
|
1812 (95.8%)
|
30 (7.3%)
|
< 0.0001
|
|
PTCy
|
79 (4.2%)
|
383 (92.7%)
| |
|
In vivo T-cell depletion
| | | |
|
No ATG
|
1537 (81.3%)
|
352 (85.2%)
|
0.058
|
|
ATG
|
354 (18.7%)
|
61 (14.8%)
| |
- MSD: matched sibling donor, Haplo: haploidentical transplantation, MAC: myeloablative conditioning, RIC: reduced intensity conditioning, TBI: total body irradiation; BM: bone marrow; PB: mobilized peripheral blood stem cells; PTCy: post-transplantation cyclophosphamide; ATG: anti-thymocyte globulin; MAC: myeloablative conditioning; TBI: total body irradiation; CT: chemotherapy; RIC: reduced intensity conditioning
